Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned a consensus recommendation of “Hold” from the ten research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $68.00.
Several equities research analysts recently weighed in on the company. Stifel Nicolaus began coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. Wells Fargo & Company reduced their target price on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. Piper Sandler lifted their price target on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. The Goldman Sachs Group upped their price objective on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Finally, Wolfe Research initiated coverage on shares of Solventum in a report on Thursday, September 26th. They set a “peer perform” rating for the company.
Check Out Our Latest Research Report on SOLV
Institutional Trading of Solventum
Solventum Trading Up 1.7 %
Shares of SOLV stock opened at $70.81 on Thursday. The stock has a fifty day moving average of $70.53 and a 200 day moving average of $62.33. Solventum has a 52 week low of $47.16 and a 52 week high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Read More
- Five stocks we like better than Solventum
- Investing In Automotive Stocks
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 11/18 – 11/22
- About the Markup Calculator
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.